Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...

Co-hosted by Veronica Green, the aim was to bring attention to the importance of communicating both symptoms and feelings ...

In true form, BIO-Europe will mark its 30th anniversary in Stockholm, Sweden, from November 4-6, 2024. The Nordic region ...

Now, the FDA has added three new products to its list of medicines in short supply as a result of the plant being taken ...

The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, ...

The consultation on raising the threshold suggests that this change will “ensure that the BIT continues to target those ...

MERGE announces new Chair. MERGE, a Chicago-based integrated technology and marketing services provider, has a new board ...

Sanofi said in October last year that it was planning to spin off its consumer health business into a separate company before ...

Between digital therapeutics, HCP portals, and patient support communications, pharma companies are investing a significant ...

Novartis' Piqray/Vijoice (alpelisib) is the only PIK3CA inhibitor to have reached the market for breast cancer, having been ...

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give ...